GoldenGolden
Felix Biotechnology

Felix Biotechnology

Biotherapeutics company focused on microbial challenges such as antibiotic-resistant bacterial infection for which the company aims to develop and deploy precision phage therapy

Felix Biotechnology is a biotherapeutics company with a focus on microbial challenges in human health. Felix Biotechnology is developing precision phage therapy to manage antibiotic-resistant bacterial infection, using a phage licensed from Yale University and discovery and engineering platforms from University of Califoria Berkeley.

Felix Biotechnology’s technology has been deployed to treat multidrug resistant (MDR) bacteria and pan-drug resistant (PDR) Pseudomonas aeruginosa infections in cystic fibrosis patients using a compassionate use IND. The company also has candidates to target S. aureus, MRSA infections, Burkhholderia and Acinetobacter as well as discovery biotherapeutics targeting certain fungal infections.

Timeline

January 7, 2021
Felix Biotechnology announces initiation of the CYPHY Phase 1/2 study at Yale for its lead asset targeting P. aeruginosa infections.

People

Name
Role
LinkedIn

Paul Turner

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Felix Biotechnology, Inc.
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Felix Biotechnology today announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.